Patients with type 2 diabetes have disproportionately elevated fasting glucagon levels and also exhibit reduced early glucose-induced suppression of glucagon secretion in response to an oral glucose tolerance test (OGTT) [2]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.